Analyst Reco. Prothena Corporation plc

Equities

PRTA

IE00B91XRN20

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
21.13 ^USD	-2.54%		+1.54%	-41.85%

May. 28	Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License	MT
May. 28	Prothena Announces Bristol Myers Squibb Opt-In for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RBC Cuts Price Target on Prothena to $28 From $35, Keeps Sector Perform, Speculative Risk	May. 09	MT
Oppenheimer Cuts Prothena Price Target to $80 From $98, Maintains Outperform Rating	Feb. 20	MT
RBC Trims Price Target on Prothena to $35 From $36, Keeps Sector Perform, Speculative Risk	Feb. 16	MT
RBC Cuts Price Target on Prothena to $36 From $43, Calls Initial Data on PRX012 'Anticlimactic,' Keeps Sector Perform, Speculative Risk	Jan. 25	MT
Deutsche Bank Initiates Coverage on Prothena With Buy Rating, $62 Price Target	Dec. 12	MT
RBC Cuts Price Target on Prothena to $43 From $60, Keeps Sector Perform, Speculative Risk	Nov. 02	MT
JMP Securities Adjusts Prothena's Price Target to $83 From $82, Keeps Market Outperform Rating	23-08-04	MT
Cantor Fitzgerald Adjusts Prothena Price Target to $120 From $98, Maintains Overweight Rating	23-05-08	MT
HC Wainwright Adjusts Price Target on Prothena to $90 From $75, Maintains Buy Rating	23-05-05	MT
RBC Boosts Price Target on Prothena to $60 From $55, Maintains Sector Perform, Speculative Risk	23-05-05	MT
SVB Securities Starts Prothena at Outperform With $80 Price Target	23-04-24	MT
Citigroup Adjusts Price Target on Prothena to $72 From $76, Keeps Buy Rating	23-02-27	MT
RBC Trims Price Target on Prothena to $55 From $56, Keeps Sector Perform, Speculative Risk	23-02-24	MT
Piper Sandler Starts Prothena at Overweight With $94 Price Target	23-01-27	MT
RBC Lifts Price Target on Prothena to $56 From $55, Maintains Sector Perform Rating	23-01-13	MT
Cantor Fitzgerald Adjusts Price Target on Prothena to $98 From $91, Maintains Overweight Rating	22-12-21	MT
Oppenheimer Adjusts Prothena Price Target to $120 From $110, Maintains Outperform Rating	22-11-15	MT
RBC Downgrades Prothena to Sector Perform From Outperform, Citing Valuation, Lifts Price Target to $55 From $52, Keeps Speculative Risk Qualifer	22-11-04	MT
Citigroup Adjusts Prothena's Price Target to $71 From $65, Reiterates Buy Rating	22-10-24	MT
Oppenheimer Adjusts Prothena Price Target to $110 From $100, Maintains Outperform Rating	22-09-29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Prothena Corporation plc

Equities

PRTA

IE00B91XRN20

Analyst Reco.

Filters